載入中
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
一般交易時段
US$10.29
US$0.00 · -0.00%
盤中時間採用ET。市場資料可能有所延遲。
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
日內區間
目前US$10.29
52週區間
目前US$10.29
盤中時間採用ET。市場資料可能有所延遲。
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
日內區間
目前US$10.29
52週區間
目前US$10.29
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV2486.36萬0.08%309.17億 USD0.25%US$120.55+0.51%
Vanguard Morningstar Total Stock Market ETFVTI1223.58萬0.00%2.3兆 USD0.03%US$381.24-0.09%
iShares Russell 2000 ETFIWM1203.59萬0.02%787.4億 USD0.19%US$276.98-0.33%
Vanguard Extended Market ETFVXF418.73萬0.00%954億 USD0.05%US$232.71-0.35%
Dimensional - US Targeted Value ETFDFAT410.49萬0.01%302.16億 USD0.33%US$67.795+0.56%
Dimensional - US Small Cap ETFDFAS402.59萬0.01%338.04億 USD0.31%US$78.325+0.20%
iShares Russell 2000 Value ETFIWN368.09萬0.03%137.49億 USD0.24%US$211.02-0.04%
EA Bridgeway Omni Small-Cap Value ETFBSVO254萬0.11%23.99億 USD0.45%US$28.615+0.40%Avantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATDimensional - US Small Cap ETFDFASiShares Russell 2000 Value ETFIWNEA Bridgeway Omni Small-Cap Value ETFBSVOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
